Small-Cap Momentum Watch: Upcoming Catalysts for April 20–24

From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.

--

Companies Presenting at The AACR 2026 Annual Meeting

The AACR 2026 Annual Meeting will take place from April 17–22, 2026, at the San Diego Convention Center in San Diego, California. The AACR Annual Meeting is the focal point of the cancer research community, bringing together scientists, clinicians, healthcare professionals, survivors, patients, and advocates to share the latest advances in cancer science and medicine. The meeting spans population science and prevention, cancer biology, translational and clinical studies, survivorship, and advocacy, highlighting research from leading institutions around the world.

Presenting companies for April 20–22 include: IMRX • BCTX • FHTX • ZNTL • TOVX • ACRV • MOLN AGEN • CLDI • XLO • LTRN • CATX • TELO • MYGN QTRX • FATE • NUVB • PRLD • IPHA • BYSI • ATNM SLS • CNTX • PYXS • INMB • BOLD • HIND • EVAX QSI • MIRA • AKTX • GNPX • BFRG

Other Companies with Material Events This Week:

● HTLM > shareholders approved a final special cash dividend of US$0.065 per ordinary share at the April 10, 2026 annual meeting. Based on 89,687,500 outstanding shares, the estimated total payout is about US$5.8 million. The dividend is expected to be paid on April 30, 2026, to shareholders of record as of April 22, 2026

● SND > board declared a special cash dividend of $0.10 per share, payable May 5, 2026, to stockholders of record as of April 22, 2026

● IMUX > management, medical, and preclinical teams will attend the 2026 American Academy of Neurology Annual Meeting in Chicago from April 18–22, 2026, and will be available throughout the event at booth #3830

● CRVO > new findings from MRI analyses in the Phase 2b RewinD-LB trial will be included in a clinical update and additional data will be presented in a poster session at the 2026 American Academy of Neurology Annual Meeting in Chicago on Wednesday, April 22, 2026. The analysis provides preliminary evidence that neflamapimod may reduce basal forebrain atrophy in DLB and supports MRI as a tool for future studies

● DVLT > CEO Nathaniel T. Bradley will deliver a keynote at CONV3RGENCE London & The Digital Commonwealth Awards 2026 on April 22, 2026, at Mansion House in London

● SABS > will give an oral presentation and multiple posters at the 21st Immunology of Diabetes Society Congress in Brisbane, Australia, from April 20–24, 2026, highlighting SAB-142 for newly diagnosed Stage 3 T1D patients

● BIVI > an abstract from the SUNRISE-PD study of bezisterim (NE3107) in Parkinson’s disease has been accepted for presentation at the AAN Annual Meeting in Chicago, April 18–22, 2026. The poster will be presented Monday, April 20, from 5:00–6:00 p.m. CT during the Movement Disorders session

● ENTX > will host a virtual Key Opinion Leader webinar on Monday, April 20, 2026, at 11:00 a.m. ET focused on the osteoporosis treatment landscape and the opportunity for EB613, its oral PTH (1-34) tablet

● CABA > complete Phase 1/2 data from three RESET trials are expected in 1H26, with RESET-MG data scheduled for an oral presentation at the AAN Annual Meeting in Chicago on Monday, April 20, 2026, at 1:24 p.m. CDT. The company expects these data to support FDA discussions on potential registrational pathways

● EHTH > two senior leaders will participate in panel discussions at Medicarians 2026 in Las Vegas from April 20–22, 2026. Brad Rocque will speak on “ICHRA & Other Alternative Solutions” on Monday, April 20, from 4:20–5:00 p.m.

● CYCU > will participate in a live online investor event hosted with FORCE Family Office on April 21, 2026, at 12:00 p.m. ET / 9:00 a.m. PT, featuring Chairman and CEO Kevin Kelly

● GPUS > will host a conference call and webcast after market close on Tuesday, April 21, 2026, to provide a corporate update on its Michigan AI data center campus

● TYGO > will present at the Zonna Solar Conference in Berlin, Ohio, from April 21–22, 2026, highlighting residential solar repowering strategies using the Tigo GO Optimized ESS platform and demonstrating related solutions

● IMDX > positive real-world head-to-head data on the GraftAssure™ assay will be presented at the 39th European Immunogenetics and Histocompatibility Conference (EFI2026) in Edinburgh, Scotland, from April 21–24, 2026

● NXL > RedChip will host an investor webinar with Nexalin on April 21, 2026, at 4:15 p.m. ET. CEO Mark White will discuss DIFS™ technology, clinical evidence, next-generation products including HALO™ Clarity and the Virtual Clinic platform, and the company’s commercialization strategy

● CODX > will participate in ESCMID Global 2026 in Munich, Germany, from April 17–21, 2026

● UAVS > EagleNXT and Dilectro will jointly showcase the eBee drone series at POLSECURE in Kielce, Poland, from April 21–23, 2026, highlighting drones on the U.S. Department of Defense Blue UAS Cleared list

● ABCL > will participate in the Bloom Burton & Co. Healthcare Investor Conference on April 21–22, 2026

● LXRX > results from the PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain will be presented Wednesday, April 22, during the AAN Annual Meeting in Chicago. The company will also present preclinical results on spasticity-related endpoints in multiple sclerosis and spinal cord injury models

● ZENA > ZenaDrone will showcase AI drone solutions at Sea-Air-Space 2026 from April 19–22, 2026, in National Harbor, Maryland, including ISR, heavy-lift cargo, indoor inventory, counter-UAS, interceptor, and underwater drone systems

● ATHE > Dr. Daniel Claassen will deliver a late-breaking oral presentation at the AAN Annual Meeting in Chicago on Tuesday, April 21, 2026, at 6:21 p.m. CT, on ATH434 and its disease-modifying signal in multiple system atrophy

● VERI > will showcase Discovery Content Intelligence with VERI at the 2026 NAB Show in Las Vegas from April 19–22, 2026, at booth #W1453 in the West Hall

● MDCX > will present new Phase 1 clinical data on Teverelix at the AACE 2026 Annual Meeting in Las Vegas, April 22–24, 2026

● GRCE > an abstract from the STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the AAN Annual Meeting in Chicago, with poster presentation scheduled for April 21, 2026, at 1:00 p.m. CT. The company also noted the FDA PDUFA target date of April 23, 2026 for GTx-104

● INO > will participate in the World Federation of Hemophilia World Congress in Kuala Lumpur on Wednesday, April 22, 2026, with an oral presentation at 9:45 a.m. MYT and a poster presentation at 10:45 a.m. MYT on its DNA medicine platform for hemophilia A

● LOT > will return to Milan Design Week with “IN PROGRESS,” an exhibition running April 22–26, 2026, created with Haus of Automotive and powered by Konzepthaus

● AEON > will present a poster at the AAN Annual Meeting in Chicago on Wednesday, April 22, 2026, from 11:45 a.m.–12:45 p.m. CT, on primary structure comparability between ABP-450 and onabotulinumtoxinA to support biosimilarity

● GPRO > will debut a new generation of GP3-powered cameras at the 2026 NAB Show, April 19–22, 2026, at Booth C5519, with focus on improved processing, larger sensors, and enhanced low-light performance

● BTAI > will host a virtual event on Thursday, April 23, 2026, from 2:00–3:00 p.m. ET focused on commercial launch strategy for IGALMI® ahead of the November 14 PDUFA date for at-home acute agitation treatment

● ADGM > its Ultra-low Temperature Ablation technologies for scar-related ventricular tachycardia will be featured in several presentations at Heart Rhythm 2026 in Chicago from April 23–26, 2026

● NXGL > moved up its shareholder update conference call to Tuesday, April 21, 2026, at 4:30 p.m. ET to discuss the Celularity transaction

● PMI > will participate in the ISHLT 2026 Annual Meeting in Toronto, with a poster presentation on “The Emperor Total Artificial Heart” scheduled for April 24, 2026, from 4:30–5:30 p.m. in the Poster Hall

● YHC > entered into a Share Purchase Agreement to acquire 100% of Fusion Five Continents Limited in multiple tranches for up to $126.88 million. The initial closing for a 24% stake is expected no later than April 24, 2026, subject to regulatory approvals

● AVX > will sponsor the Cornell Blockchain Conference 2026, and CEO Jolie Kahn will participate as a speaker on April 24, 2026

● BLZE > will host a series of partner showcases at the 2026 NAB Show in Las Vegas from April 18–22, 2026, highlighting modern media workflows, AI technologies, and content production, protection, and distribution

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.